Trading Signals: TBIO Stock Price Prediction and Forecast (Thu. Jun. 28, 2018 - Tue. Feb. 14, 2023)(Translate Bio, Inc)
| TBIO latest price $13.5950 (-0.33%) ($13.4500 - $13.9500) on Wed. Sep. 30, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.75% (three month average) | RSI | 56 | Latest Price | $13.5950(-0.33%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TBIO advances 1.8% a day on average for past five trading days. | Weekly Trend | TBIO declines -1.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TBIO advance at 0% a week (0% probability) XBI(43%) IBB(41%) ARKG(33%) IWO(33%) ARKK(30%) | Factors Impacting TBIO price | TBIO will decline at least -1.875% in a week (0% probabilities). VXX(-20%) VIXM(-15%) UUP(-9%) TBT(-7%) IGOV(-4%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.875% (StdDev 3.75%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $13.24(2.68%) | 10 Day Moving Average | $13.49(0.78%) | 20 Day Moving Average | $13.42(1.3%) | To recent high | -31.2% | To recent low | 9.2% | Market Cap | $943m | | | | Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.June 23, 2020 - Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases. The expansion of this agreement will further unite Translate Bio’s expertise and knowledge from more than 10 years of mRNA research and development with Sanofi’s leadership in vaccine research and development. Under the expansion agreement, Translate Bio will receive a total upfront payment of $425 million, consisting of a $300 million cash payment and a private placement common stock investment of $125 million at $25.59 per share representing a 50 percent premium to the 20-day moving average share price prior to signing. Translate Bio will also be eligible for potential future milestones and other payments up to $1.9 billion |